Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has maintained a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $82 to $90, indicating a positive outlook on the company's stock.
April 22, 2024 | 4:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Intra-Cellular Therapies and raises the price target from $82 to $90.
The increase in price target by a reputable analyst suggests a strong confidence in the company's future performance, likely leading to positive investor sentiment and a potential increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100